News and Trends 1 Feb 2017 Stem Cell Therapy for Sepsis in Pneumonia advances to Phase II TiGenix has treated the first patient in a new early-stage clinical trial to test its candidate Cx611 as a treatment for sepsis in patients with pneumonia. TiGenix, based in Belgium, develops stem cell therapies derived from donors. This morning, the first patient was treated in a Phase Ib/IIa clinical trial for its candidate therapy Cx611 in […] February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2017 ‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired antibody fragments, VNARs, with outstanding properties thanks to their small size and high solubility. The company has now received a milestone payment from Danish pharma Lundbeck for the development of the technology as a delivery […] January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2017 Genetically Engineered Mosquitoes will arrive in India to fight Dengue Oxitec is preparing to start trials testing its solution to reduce the population of disease-transmitting insects in India with its own genetically modified mosquitoes. Oxitec, a spin-out from Oxford University, engineers mosquitoes to reduce their populations in areas where they spread infectious diseases. After success in Brazil and the Cayman Islands, the company is now heading […] January 25, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2017 New Fundraising Boosts Ultra-Rapid STD Detection Atlas Genetics has raised €32.6M in Series D. The funds will help the company bring ultra-rapid diagnostic tests for STDs to the market. Atlas Genetics, a spin-off from the University of Bath, has closed an impressive €32.6M ($35M) Series D round of fundraising. The funds will support clinical trials, manufacturing and the commercial launch of the company’s second ultra-rapid […] January 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 17 Jan 2017 Nanoparticles from Car Tailpipes could Activate Viruses in the Lungs Nanoparticles produced by burning fossil fuels could promote viral infections by activating latent viruses in our lungs; what are the consequences? We all know that breathing the traffic smoke is not good for our health. Now, researchers from the Helmholtz Zentrum in Munich have discovered a process that makes it even more dangerous than initially […] January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2017 This Herpes Cure is Proving to Work Better than its Predecessors AiCuris’ candidate pritelivir has shown to perform better than current standard antiviral treatments against genital herpes in Phase II trials. AiCuris, leading the development of treatments for infectious disease, has completed a Phase II trial in which its candidate pritelivir outperformed the current standard care for genital herpes. When compared to the antiviral drug valacyclovir, […] January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2017 An Antibody to reduce Hospitalizations of Children starts Phase IIb trials Ablynx has treated its first patient in a new trial targeting RSV infections, the main cause of children hospitalizations. Ablynx, one of the few European biotechs that made it into JP Morgan this year, develops nanobodies derived from llamas. The Belgian company announced yesterday that its candidate ALX-0171 has entered testing in Phase IIb as a treatment […] January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2017 Phase II Failure: CureVac’s CEO explains Missed Efficacy Endpoint Money doesn’t guarantee success, even if it’s heavy investment from the likes of the Bill & Melinda Gates Foundation. Ingmar Hoerr explains what it means for mRNA therapeutics. In a blow to the field of mRNA, the German billion-euro biotech CureVac has reported the Phase II failure of its lead candidate at JP Morgan. Aimed at prostate cancer, CV9104 did not […] January 11, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2017 Cold Sore Cure Company enters the Antibiotic Resistance fight AiCuris is developing a new antibiotic that might bring hope for patients in which all options to fight infections have been exhausted. AiCuris, a German company leading the fight against infectious diseases, is now entering clinical trials with a new antibiotic. The candidate, AIC499, is a β-lactam effective against a broad range of Gram-negative multi-drug resistant […] January 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2017 Bacteria can Protect each other: a New Challenge in Antibiotic Resistance Researchers have discovered a new mechanism by which antibiotic-resistant bacteria can protect non-resistant pathogens. What are the implications? Scientists have described a new strategy that pathogens use to survive our efforts to eliminate them: resistant bacteria can inactivate antibiotics and allow their neighbor pathogens to grow once the active compound has reached low enough levels. The […] January 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Jan 2017 10 Hot European Biotechs to Observe in 2017 🚀 New year, new list: here are the 10 hottest Biotech companies I will watch closely in 2017 and why. This list is not meant to be comprehensive and is in no particular order. Super-pumped mRNA Therapy BioNTech is Europe’s largest private Biotech with over 500 employees and is one of the three leading mRNA therapy […] January 3, 2017 - 5 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2016 How Will Biotech Overcome the Huge Challenges of Microbial Resistance? The emergence of multi-drug resistant pathogens is alarming the scientific community since their growth is increasing at an incredibly fast pace. We gathered a group of experts to discuss how biotech is addressing this pressing concern and what the next big thing will be in the field of antimicrobial resistance. Achim Plum, CCO of Curetis, highlighted that […] December 13, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email